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 ■ INTRODUCTION
Anal abscess is one of the most common anorectal diseases 
that often occurs in young males between the ages of 30 and 50 
years. The abscesses originate from cryptoglandular infection of 
proctodeal glands in the intersphincteric space. They are classified 
into perianal, ischiorectal, intersphincteric, and supralevator types 
based on the anatomical location (1). Patients present with acute 
onset of pain and swelling in the perianal region. The incidence is 
16.1-20.2 per 100,000 per year, and the rate of subsequent fistula 
formation following an abscess is 15.5% (2,3). The reported risk 
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OBJECTIVES: We conducted this retrospective study to elucidate the clinical presentation and outcomes of anal 
abscess in chronic dialysis patients.
METHODS: We performed a chart review of patients who were hospitalized for anal abscess from Jan. 2002 to Dec. 
2015. A total of 3,074 episodes of anal abscess were identified. Of these, 43 chronic dialysis patients with first-time 
anal abscess were enrolled. Patients were divided into a surgical group and a nonsurgical group according to the 
treatment received during hospitalization. The baseline characteristics, clinical findings, treatments and outcomes 
were obtained and analyzed. The endpoints of this study were in-hospital mortality, one-year mortality and 
one-year recurrence.
RESULTS: Of the 43 patients, 27 (62.7%) received surgical treatment, and 16 (37.2%) received antibiotic treatment 
alone. There was no significant difference in age, sex, body mass index, smoking habits, comorbidities, or dialysis 
characteristics between the two groups. Perianal abscess was the most common type of anal abscess, and 39.5% of 
patients experienced fistula formation. Most patients had mixed aerobic and anaerobic flora. Our data demonstrate 
that there was no significant difference in hospital stay, one-year survival or recurrence rate between the surgical 
group and nonsurgical group. However, there was a trend toward better in-hospital survival in patients who received 
surgical treatment (p=0.082).
CONCLUSION: In chronic dialysis patients with anal abscess, there was no statistically significant difference in clinical 
presentation and outcomes between the surgical and nonsurgical groups, although the surgical group had a trend 
of better in-hospital survival.
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factors of anal abscess include diabetes mellitus (DM), obesity, 
alcohol use, recent smoking, high daily salt intake, sedentary 
lifestyle, straining at defecation and psychosocial stress (3,4,5,6). 
Surgical incision and drainage are usually recommended even in 
cases of spontaneous perforation (7,8). Surgical treatment helps for 
decompression and pain relief of the abscess and prevents pelvic 
sepsis or Fournier’s gangrene formation. Antibiotic treatment alone 
is thought to be inappropriate and leads to treatment failure, disease 
recurrence, and fistula formation. 
Patients with end stage renal disease (ESRD) who need 
chronic dialysis have an increased operative risk for anorectal 
surgery because they have one or more comorbidities, anemia from 
chronic kidney disease and uremia-related platelet dysfunction. 
Considering the intraoperative risk and the postoperative care, 
treatment of anal abscess in chronic dialysis patients tends to be 
more conservative than in the general population. However, only a 
few small case series of anal abscess in chronic dialysis patients can 
be found in the literature (9,10). The clinical course and outcomes 
in dialysis patients with anal abscess have not been well described. 
This study was conducted to elucidate the clinical presentations, 
patient survival and recurrence of anal abscess in hospitalized 
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chronic dialysis patients. The study also evaluated the outcomes in 
patients with and without surgical treatment during hospitalization.
 ■ MATERIALS AND METHODS 
This study was performed by retrospectively reviewing 
the medical records from all consecutive patients who were 
hospitalized for anal abscess. The study was conducted in a tertiary 
hospital in Taiwan (Chang Gung Memorial Hospital, Linko, 
Taiwan) from Jan. 2002 to Dec. 2015. Patients with a discharge 
diagnosis of anal abscess, which was defined as International 
Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) code 566, were identified. Chronic dialysis patients 
were identified by using chart review and the charge codes of 
hemodialysis or peritoneal dialysis. The date of admission was 
defined as the index date.
A total of 3,074 episodes of anal abscess were found in the 
14-year study period using the ICD-9-CM code 566. Among 
these, 91 had incident dialysis. All dialysis patients were above 
20 years of age. We excluded patients who initiated dialysis after 
the index date (n=23), patients who did not fit the diagnosis of anal 
abscess in chart review (n=11) and patients who had inflammatory 
bowel disease (n=1). Recurrent episodes of anal abscess were 
also excluded (n=13). Forty-three chronic dialysis patients who 
were hospitalized for first-time anal abscess were enrolled and 
analyzed (Figure 1). 
The study reviewed the patient’s baseline characteristics and 
comorbidities. The dialysis-associated factors, including primary 
cause of ESRD, duration of renal replacement therapy and type 
of dialysis access, were also documented. Patients were divided 
into two groups according to whether they received surgical 
intervention during the index admission. The surgical procedure 
was defined as any incision and drainage of the abscess with or 
without anal fistulotomy and fistulectomy. We also recorded the 
clinical presentation, the type of abscess, the microbiology and the 
occurrence of fistula formation. Patient outcomes were evaluated 
during hospitalization and 1 year after admission. The endpoints 
of this study were in-hospital mortality, one-year mortality and 
one-year recurrence.
Analysis was conducted using R 3.2.4 software (R Project for 
Statistical Computing, Vienna, Austria). Descriptive statistics are 
presented as the mean ± standard deviation for continuous data 
Figure 1 – Flow chart of patient selection.
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and count (%) for categorical data. The t-test and Fischer’s exact 
test were applied in the comparison of surgically and nonsurgically 
treated patients. A two-sided p-value of 0.05 was considered 
statistically significant. The follow-up time ended when patients 
died, relapsed, or were recurrence-free for one year. 
Ethics 
The study methods are in accordance with the ethical standards 
of the responsible committee on human experimentation and with 
the Helsinki Declaration. The Institutional Review Board of Chang 
Gung Memorial Hospital approved this study (IRB Approval No. 
2016009714B0).
 ■ RESULTS 
Forty-three dialysis patients who were hospitalized for anal 
abscess for the first time were identified in 3,074 episodes of anal 
abscess in the 14-year study period. The baseline characteristics 
of the chronic dialysis patients with anal abscess are illustrated 
in Table 1. The average age was 59.98±11.93 years old. Male 
predominance was noted in these patients (n=33, 76.7%). The 
body mass index (BMI) was 24.20±3.89 kg/m2; 37.2% of the 
patients (n=16) had recently smoked; 53.5% of the patients had 
hypertension (n=25); 58.1% of the patients had DM (n=25); 
14.0% of the patients had coronary artery disease (n=6); 7.0% 
of the patients had congestive heart failure (n=3); 16.3% of the 
patients had a cerebral vascular accident (n=7); 9.3% of the 
patients had chronic hepatitis B (n=4); 25.6% of the patients 
had chronic hepatitis C (n=11); 16.3% of the patients had liver 
cirrhosis (n=7); and 16.3% of the patients had malignancy 
(n=7). We also found that 62.8% of the patients had constipation 
(n=27), and 16.3% of the patients had hemorrhoids (n=7). The 
two major primary causes of ESRD were diabetic nephropathy 
(n=15, 34.9%) and chronic glomerulonephritis (n=23, 53.5%). 
The duration of renal replacement therapy ranged from 2 months 
to 28 years (median=3.94 years). In these patients, 65.1% used 
an arteriovenous fistula (n=28), 14.0% used an arteriovenous 
Table 1 - Baseline characteristics of chronic dialysis patients with anal abscess.
Characteristics
All
(N=43)
Surgical
(N=27)
Nonsurgical
(N=16)
p-value
Age, year 59.98±11.93 59.59±12.35 60.63±11.56 0.788
Male gender, n (%) 33 (76.7) 21 (77.7) 12 (75.0) 1.000*
Body mass index, kg/m2 24.20±3.89 24.12±4.06 24.38±3.62 0.857
Recent smoking, n (%) 16 (37.2) 11 (40.7) 5 (31.3) 0.534
Comorbidity, n (%)
Hypertension 23 (53.5) 14 (51.9) 9 (56.2) 0.780
Diabetes mellitus 25 (58.1) 17 (63.0) 8 (50.0) 0.405
Coronary artery disease 6 (14.0) 2 (7.4) 4 (25.0) 0.174*
Congestive heart failure 3 (7.0) 2 (7.4) 1 (6.3) 0.545*
Cerebral vascular accident 7 (16.3) 3 (11.1) 4 (25.0) 0.394*
Chronic hepatitis B 4 (9.3) 1 (3.7) 3 (18.8)
Chronic hepatitis C 11 (25.6) 6 (22.2) 5 (31.3)
Cirrhosis 7 (16.3) 2 (7.4) 5 (31.3) 0.082* 
Malignancy 7 (16.3) 3 (11.1) 4 (25.0) 0.394* 
Constipation 27 (62.8) 19 (70.4) 8 (50.0) 0.182 
Hemorrhoids 7 (16.3) 5 (18.5) 2 (12.5) 0.695* 
Primary cause of end-stage renal disease 1.000*
Diabetic nephropathy  15 (34.9) 9 (33.3) 6 (37.5)
Chronic glomerulonephritis 23 (53.5) 15 (55.5) 8 (50.0)
Others 5 (11.6) 3 (11.1) 2 (12.5)
Duration of renal replacement therapy, 
median days, (lower quartile-upper quartile)
1,439
(633-2,779)
1,381 (678-1,813.5)
2,001.5
(730.25-3,091.5)
0.462#
Type of dialysis access, n (%) 0.769*
Arteriovenous fistula 28 (65.1) 17 (63.0) 11 (68.8)
Arteriovenous graft 6 (14.0) 4 (14.8) 2 (12.5)
Tunneled cuffed catheter 3 (7.0) 1 (3.7) 2 (12.5)
Nontunneled central venous catheter 1 (2.3) 1 (3.7)  0 (0.0)
Peritoneal dialysis 5 (11.6) 4 (14.8) 1 (6.3)
* Fisher’s exact test.
# Mann-Whitney test.
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graft (n=6), 7% used a tunneled cuffed catheter (n=3), 2.3% used 
a nontunneled central venous catheter (n=1), and 11.6% used 
peritoneal dialysis (n=5) as their dialysis accesses. The study 
showed that 62.8% of chronic dialysis patients with anal abscess 
(n=27) received surgical treatment during hospitalization, and 
37.2% of patients (n=16) received medical treatment alone. There 
was no significant difference in age, sex, BMI, recent smoking, 
comorbidities, or dialysis characteristics between the surgical and 
nonsurgical groups (Table 1).
Less than half of the patients presented with fever (n=21, 
48.8%) at admission. Perianal abscess (n=37, 86.0%) was the 
most common type of abscess in both the surgical and nonsurgical 
groups, whereas ischiorectal abscess (n=3, 7.0%), intersphincteric 
abscess (n=2, 4.7%) and supralevator abscess (n=1, 2.3%) were also 
found in chronic dialysis patients. Seventeen patients (39.5%) had 
an anal fistula the first time they were diagnosed with anal abscess. 
There was no significant difference in clinical presentation or type 
of abscess between the surgical and nonsurgical groups (Table 2).
The most common pathogens grown in abscess cultures were 
mixed aerobic and anaerobic flora (n=16, 37.2%). Three patients 
had both Gram-positive aerobic and Gram-negative aerobic 
bacteria (7.0%), 6 patients had Gram-positive aerobic bacteria 
alone (14.0%), 3 patients had Gram-negative aerobic bacteria 
alone (7.0%), and 1 patient had anaerobic bacteria (2.3%). Most 
patients who did not have a culture result (n=14, 32.6%) did not 
send an abscess culture. The isolated microorganisms from anal 
abscesses are shown in Table 3. Streptococcus spp., Enterococcus 
spp., and Staphylococcus spp. were common Gram-positive 
Table 2 - Clinical characteristics and outcomes of chronic dialysis patients with surgical and nonsurgical treatments. 
Characteristics
All
(N=43)
Surgical
(N=27)
Nonsurgical
(N=16)
p-value
Fever, n (%) 21 (48.8) 13 (48.1) 8 (50.0) 0.907
Type of abscess, n (%)
Perianal 37 (86.0) 22 (81.5) 15 (93.8) 0.386* 
Ischiorectal 3 (7.0) 3 (11.1) 0 (0.0) 0.282* 
Intersphincteric 2 (4.7) 1 (3.7) 1 (6.3) 1.000* 
Supralevator 1 (2.3) 1 (3.7) 0 (0.0) 1.000* 
Fistula formation, n (%) 17 (39.5) 10 (37.0) 7 (43.8) 0.663
Microbiology, n (%) 0.077*
Mixed aerobic and anaerobic flora 16 (37.2) 13 (48.1) 3 (18.8)
Gram-positive and Gram-negative aerobic bacteria 3 (7.0) 1 (3.7) 2 (12.5)
Gram-positive aerobic bacteria only 6 (14.0) 4 (14.8) 2 (12.5)
Gram-negative aerobic bacteria only 3 (7.0) 3 (11.1) 0 (0.0)
Anaerobic bacteria only 1 (2.3) 0 (0.0) 1 (6.3)
No culture result 14 (32.6) 6 (22.2) 8 (50.0)
Laboratory examination
White blood cell count, cells/ml 14,519.05±7,204.28 13,253.33±4,520.09 15,222.22±8,331.00 0.403 
Hemoglobin, g/dL 10.21±1.83 9.91±1.91 10.38±1.80 0.427 
C-reactive protein, mg/mL 158.56±100.29 172.38±97.70 152.74±103.43 0.651 
Albumin, g/dL 3.07±0.53 3.20±0.82 3.00±0.35 0.626 
Antibiotic treatment 40 (93.0) 25 (92.6) 15 (93.8) 1.000* 
Hospital stay, days 20.70±21.11 19.33±23.87 23.00±15.87 0.588 
In-hospital survival, n (%) 36 (83.7) 25 (92.6) 11 (68.8) 0.082* 
One-year survival, n (%) 33 (76.7) 23 (85.2) 10 (62.5) 0.137* 
One-year recurrence, n (%) 5 (13.9) 3 (12.0) 2 (18.2) 0.631* 
* Fisher’s exact test.
Table 3 - Isolated microorganisms from anal abscesses of chronic 
dialysis patients.
Microorganisms n (%)
Gram-positive aerobic bacteria
Streptococcus spp. 8 (27.6)
Enterococcus spp. 6 (20.7)
Staphylococcus aureus 4 (13.8)
Coagulase-negative Staphylococci 2 (6.9)
Stenotrophomonas maltophilia 1 (3.4)
Gram-negative aerobic bacteria
Escherichia coli 10 (34.5)
Klebsiella spp. 4 (13.8)
Proteus spp. 2 (6.9)
Citrobacter diversus 1 (3.4)
Acinetobacter junii 1 (3.4)
Anaerobic bacteria
Bacteroides spp. 14 (48.3)
Prevotella spp. 4 (13.8)
Peptostreptococcus spp. 3 (10.3)
Fusobacterium spp. 3 (10.3)
Clostridium spp. 1 (3.4)
Veillonella spp. 1 (3.4)
Yeast 4 (13.8)
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aerobic bacteria. Escherichia coli and Klebsiella spp. were 
common Gram-negative aerobic bacteria. Bacteroides spp. was 
the most common anaerobic bacteria in this study. Yeast was also 
noted in 13.8% of the positive cultures.
Chronic dialysis patients with anal abscess often develop 
leukocytosis, anemia, elevated C-reactive protein and 
hypoalbuminemia. Among the 43 cases, 93.0% received 
intravenous or oral antibiotic treatment (n=40). Physicians often 
used two combined antibiotics empirically, such as ceftriaxone 
plus metronidazole, to cover the mixed aerobic and anaerobic flora. 
Antibiotics were adjusted according to the culture results. Two 
patients in the surgical group and one patient in the nonsurgical 
group did not receive intravenous or oral antibiotics. They received 
local antibiotic ointment for wound care. In the patients who 
underwent surgical intervention, 44.4% received local anesthesia 
(n=12), 25.9% received regional anesthesia (n=7), and 29.6% 
received general anesthesia (n=8).
The patient’s hospital stay was 20.70±21.11 days (median=16, 
ranged from 1-78). The in-hospital survival rate was 83.7% (n=36), 
the one-year survival rate was 76.7% (n=33), and the one-year 
recurrence rate of patients who survived during hospitalization 
was 13.9% (n=5). Septic shock and respiratory failure were causes 
of death in all patients who died during hospitalization. Patients 
died from septic shock due to anal abscess or an anal abscess 
accompanied by pneumonia, spontaneous bacterial peritonitis 
or blood stream infection. The causes of death of patients who 
died after discharge were sepsis and sudden death that was not 
related to a recurrence of anal abscess. There was no significant 
difference in survival rate or recurrence rate between the surgical 
and nonsurgical groups. However, there was a trend toward a better 
in-hospital survival rate in patients who underwent surgery for anal 
abscess at admission (92.6% vs. 68.8%, p=0.082).
 ■ DISCUSSION
This study reviewed 43 dialysis patients with first-time anal 
abscess from a tertiary medical center within a 14-year study 
period. The male to female ratio was 3.29 in dialysis patients 
with anal abscess. The average age in the study cohort was older 
than that of nondialysis patients (11). Chronic constipation and 
DM, which are commonly noted in chronic dialysis patients, 
are well-established risk factors of anal abscess. The study also 
revealed a high prevalence of chronic hepatitis (9.3% of hepatitis 
B and 25.6% of hepatitis C) and cirrhosis (16.3%) in chronic 
dialysis patients. A case series reported that two of eight patients 
with Fournier’s gangrene had liver cirrhosis or hepatoma (12). 
Although the association between liver disease and perianal 
infection had not been described in a large population-based study 
in Europe (3), further study in the chronic dialysis populations 
may be considered. 
Anal abscess may impair patient’s quality of life because of 
the resulting pain, discomfort, anxiety and depression. Although 
surgical incision and drainage have been the standard treatment, 
37.2% of the chronic dialysis patients received conservative 
treatment alone. Most of the patients in our study received a 
proctologist consultation during hospitalization. Sheikh et al. 
suggested that anorectal surgery was well tolerated in chronic 
hemodialysis patients on a well-managed dialysis program (10). 
For the patients who did not receive surgical treatment, surgery 
was not recommended by proctologists because of an unstable 
clinical condition, spontaneous perforation of the abscess, 
liquification of the abscess or excellent response to antibiotic 
treatment. The study revealed no significant difference in patient 
outcomes between the surgical and nonsurgical groups, whereas 
there was a trend toward a better in-hospital survival rate in 
patients who received surgery at admission. Although surgical 
intervention might provide a survival benefit, it is possible that 
patients receiving conservative treatment had more severe clinical 
complications that resulted in poorer outcomes.
Chronic dialysis patients with anal abscess had a high incidence 
of fistula formation (39.5%). Additionally, more than 90% of the 
patients received antibiotic treatment. In a prospective study of 
members of the general population with primary anal abscess 
in the United Kingdom, only 14.6% of the patients had an anal 
fistula when they were diagnosed with anal abscess, and 18.3% of 
the patients received postoperative antibiotics (13). Other studies 
revealed that 22.3-27.1% of the adult patients had an anal fistula 
(14,15). Fistula results from chronic inflammation of the perianal 
area that connects the abscess to skin. The reported predictors of 
fistula formation include inflammatory bowel disease, female sex, 
age and intersphincteric or ischiorectal abscess (2). A previous 
meta-analysis showed that treatment of an anal fistula at the 
same time as drainage of perianal abscess reduces the chances of 
recurrent abscess and repeat surgery (16). A recent randomized trial 
showed that postoperative prophylactic antibiotic therapy targeting 
mixed aerobic and anaerobic pathogens protected patients from 
fistula formation (14). 
Most of the pathogens in anal abscess come from the 
gastrointestinal tract and skin. Abscess cultures have often 
showed mixed aerobic and anaerobic flora. Escherichia coli, 
Staphylococci spp. and Klebsiella pneumoniae were common 
aerobic pathogens and Bacteroides spp. and Peptostreptococcus 
spp. were common anaerobic pathogens in nondialysis patients 
(15,17). The culture results of chronic dialysis patients were 
similar to those of nondialysis patients. Current evidence 
suggests that patients with ESRD are characterized by impaired 
native and adaptive immunity (18,19). Although postoperative 
antibiotics had a limited role in uncomplicated anal abscess 
(1,20), antibiotic therapy may be considered in all chronic 
dialysis patients because of their immunosuppressive status. 
The choice of empiric antibiotics should adequately cover both 
aerobic and anaerobic flora. 
This study was limited by the small number of cases, the 
single-center experience and its retrospective design. Only 43 
dialysis patients were identified in 14 years. There may have been 
selection bias imposed by the inclusion of a tertiary center. Despite 
these limitations, to our knowledge, this is the first study to focus 
on chronic dialysis patients with anal abscesses and report the 
outcomes in surgical and nonsurgical groups.
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